190 related articles for article (PubMed ID: 19167925)
1. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.
Kenemans P; Bundred NJ; Foidart JM; Kubista E; von Schoultz B; Sismondi P; Vassilopoulou-Sellin R; Yip CH; Egberts J; Mol-Arts M; Mulder R; van Os S; Beckmann MW;
Lancet Oncol; 2009 Feb; 10(2):135-46. PubMed ID: 19167925
[TBL] [Abstract][Full Text] [Related]
2. Short-term and long-term effects of tibolone in postmenopausal women.
Formoso G; Perrone E; Maltoni S; Balduzzi S; Wilkinson J; Basevi V; Marata AM; Magrini N; D'Amico R; Bassi C; Maestri E
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD008536. PubMed ID: 27733017
[TBL] [Abstract][Full Text] [Related]
3. Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial.
Sismondi P; Kimmig R; Kubista E; Biglia N; Egberts J; Mulder R; Planellas J; Moggio G; Mol-Arts M; Kenemans P
Maturitas; 2011 Dec; 70(4):365-72. PubMed ID: 22030384
[TBL] [Abstract][Full Text] [Related]
4. Short and long term effects of tibolone in postmenopausal women.
Formoso G; Perrone E; Maltoni S; Balduzzi S; D'Amico R; Bassi C; Basevi V; Marata AM; Magrini N; Maestri E
Cochrane Database Syst Rev; 2012 Feb; (2):CD008536. PubMed ID: 22336846
[TBL] [Abstract][Full Text] [Related]
5. Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy.
Bundred NJ; Kenemans P; Yip CH; Beckmann MW; Foidart JM; Sismondi P; Schoultz Bv; Vassilopoulou-Sellin R; Galta RE; Lieshout EV; Mol-Arts M; Planellas J; Kubista E
Breast Cancer Res; 2012 Jan; 14(1):R13. PubMed ID: 22251615
[TBL] [Abstract][Full Text] [Related]
6. Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial.
Vrselja A; Latifi A; Baber RJ; Stuckey BGA; Walker MG; Stearns V; Hickey M; Davis SR
Lancet; 2022 Nov; 400(10364):1704-1711. PubMed ID: 36366886
[TBL] [Abstract][Full Text] [Related]
7. Tibolone: the risk is too high.
Goodwin PJ
Lancet Oncol; 2009 Feb; 10(2):103-4. PubMed ID: 19185829
[No Abstract] [Full Text] [Related]
8. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial.
Kroiss R; Fentiman IS; Helmond FA; Rymer J; Foidart JM; Bundred N; Mol-Arts M; Kubista E
BJOG; 2005 Feb; 112(2):228-33. PubMed ID: 15663589
[TBL] [Abstract][Full Text] [Related]
9. Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients--design and baseline data 'LIBERATE' trial.
Kenemans P; Kubista E; Foidart JM; Yip CH; von Schoultz B; Sismondi P; Vassilopoulou-Sellin R; Beckmann MW; Bundred NJ; Egberts J; van Os S; Planellas J
Breast; 2007 Dec; 16 Suppl 2():S182-9. PubMed ID: 17983942
[TBL] [Abstract][Full Text] [Related]
10. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Gnant M; Pfeiler G; Dubsky PC; Hubalek M; Greil R; Jakesz R; Wette V; Balic M; Haslbauer F; Melbinger E; Bjelic-Radisic V; Artner-Matuschek S; Fitzal F; Marth C; Sevelda P; Mlineritsch B; Steger GG; Manfreda D; Exner R; Egle D; Bergh J; Kainberger F; Talbot S; Warner D; Fesl C; Singer CF;
Lancet; 2015 Aug; 386(9992):433-43. PubMed ID: 26040499
[TBL] [Abstract][Full Text] [Related]
12. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.
Bouchard P; Panay N; de Villiers TJ; Vincendon P; Bao W; Cheng RJ; Constantine G
Climacteric; 2012 Feb; 15(1):12-20. PubMed ID: 22066790
[TBL] [Abstract][Full Text] [Related]
13. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Krop IE; Mayer IA; Ganju V; Dickler M; Johnston S; Morales S; Yardley DA; Melichar B; Forero-Torres A; Lee SC; de Boer R; Petrakova K; Vallentin S; Perez EA; Piccart M; Ellis M; Winer E; Gendreau S; Derynck M; Lackner M; Levy G; Qiu J; He J; Schmid P
Lancet Oncol; 2016 Jun; 17(6):811-821. PubMed ID: 27155741
[TBL] [Abstract][Full Text] [Related]
14. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
Cuzick J; Sestak I; Cella D; Fallowfield L;
Lancet Oncol; 2008 Dec; 9(12):1143-8. PubMed ID: 18976959
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Gnant M; Pfeiler G; Steger GG; Egle D; Greil R; Fitzal F; Wette V; Balic M; Haslbauer F; Melbinger-Zeinitzer E; Bjelic-Radisic V; Jakesz R; Marth C; Sevelda P; Mlineritsch B; Exner R; Fesl C; Frantal S; Singer CF;
Lancet Oncol; 2019 Mar; 20(3):339-351. PubMed ID: 30795951
[TBL] [Abstract][Full Text] [Related]
16. The effects of tibolone in older postmenopausal women.
Cummings SR; Ettinger B; Delmas PD; Kenemans P; Stathopoulos V; Verweij P; Mol-Arts M; Kloosterboer L; Mosca L; Christiansen C; Bilezikian J; Kerzberg EM; Johnson S; Zanchetta J; Grobbee DE; Seifert W; Eastell R;
N Engl J Med; 2008 Aug; 359(7):697-708. PubMed ID: 18703472
[TBL] [Abstract][Full Text] [Related]
17. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
Dimitrakakis C; Keramopoulos D; Vourli G; Gaki V; Bredakis N; Keramopoulos A
Climacteric; 2005 Dec; 8(4):342-51. PubMed ID: 16390769
[TBL] [Abstract][Full Text] [Related]
18. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
19. Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial.
Kubista E; Planellas Gomez JV; Dowsett M; Foidart JM; Pohlodek K; Serreyn R; Nechushkin M; Manikhas AG; Semiglazov VF; Hageluken CC; Singer CF
Clin Cancer Res; 2007 Jul; 13(14):4185-90. PubMed ID: 17634547
[TBL] [Abstract][Full Text] [Related]
20. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jiang Z; Li W; Hu X; Zhang Q; Sun T; Cui S; Wang S; Ouyang Q; Yin Y; Geng C; Tong Z; Cheng Y; Pan Y; Sun Y; Wang H; Ouyang T; Gu K; Feng J; Wang X; Wang S; Liu T; Gao J; Cristofanilli M; Ning Z; Lu X
Lancet Oncol; 2019 Jun; 20(6):806-815. PubMed ID: 31036468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
